ptca.orgAngioplasty and Stents

Stents and PCI Transradial (Wrist) Approach Intravascular Guidance IVUS, FFR, OCT Diagnosis and Imaging Antiplatelet Medication Heart Attack PatientCenter Patient Forum History and Videos News and Interviews Burt's Blog The Activated Patient Blog About Us Expert Insights & Feature Articles Interview with Tejas Patel & Samir Pancholy In December 2018, Dr. Tejas Patel performed the world's first teleroboticU coronary angioplasty. Stationed 32km from the hospital and the patients, he did five PCI procedures, all successful. In this interview Dr. Patel and his colleague, Dr. Samir Pancholy, discuss telerobotic PCI. FDA Fast Tracks Shockwave IVL Device Review Shockwave's unique coronary calcium modification system has received the U.S. Food and Drug Administration's "Breakthrough Device Designation," meaning that when the device comes before the agency for approval, it will receive a priority review, potentially speeding its availability to the interventional cardiology in the U.S. STOPDAPT-2: Is a Month of DAPT Plus a Year of Clopidogrel Safe and Effective? Dr. Hirotoshi Watanabe discusses his team's recent study, published in the Journal of the American Medical Association , which demonstrated that 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority. (posted in collaboration with TCROSS NEWS ) FDA Approves Resolute DES for Use in Chronic Total Occlusions The FDA today approved an expanded indication for Medtronic's family of Resolute zotarolimus-eluting coronary stents: use in the treatment of de novo chronic total occlusions (CTO). This approval includes all Resolute DES devices, including the Resolute Onyx™ and Resolute Integrity™ DES. The First EVAR The field of endovascular repair and intervention has grown exponentially since the 1st endovascular repair of an abdominal aortic aneurysm (EVAR) was performed by Dr. Juan Parodi in 1990 in Buenos Aires. It took a while to be accepted, but today the endovascular approach is the preferred procedure to repair an AAA. This is due to the advances in medical device design and the dedication of physicians to this less invasive non-surgical approach. 5-Year Data for IN.PACT Drug-Coated Balloon in SFA Show Improved Outcomes Over Standard PTA The IN.PACT Admiral DCB bested standard percutaneous transluminal angioplasty (PTA) for repeat interventions with almost 75% of the IN.PACT cohort of patients free from re-intervention through five-years. As for safety, there were no device or procedure-related deaths in either the DCB or PTA groups at five-years. Drug-Eluting Stent Expansion Chart A useful chart for the cath lab wall, this chart, created by Dr. Ajay Kirtane and the teams at NY Presbyterian/University of Columbia Medical Center, shows the nominal and post-dilatation expansion limits for four widely-used drug-eluting stents: Synergy (Boston Scientific), Resolute Onyx (Medtronic), Xience Sierra (Abbott Vascular), and EluNIR (Medinol/Cordis). Neoatherosclerosis Five Years After BVS Implantation Dr. Noriaki Moriyama discusses the recent study, published in the Journal of the American College of Cardiology , which showed outcomes observed at five years after implantation with the Absorb Bioresorbable Vascular Scaffold (posted in collaboration with TCROSS NEWS ) Study: Similar Outcomes for 6 vs. 12 Months of DAPT for STEMI Patients Treated with Resolute Integrity DES One year is the recommended DAPT duration for STEMI patients after stenting. But this new study shows that 6 months may be adequate with certain devices: important data, especially for patient at high risk for bleeding. Medtronic's Intrepid™ Transcatheter Mitral Valve Replacement (TMVR) System The Intrepid TMVR system integrates self-expanding, dual-stent technology with a tissue valve to facilitate catheter-based implantation without the need for open-heart surgery. The Intrepid is compressed inside a hollow delivery catheter and is inserted between the ribs to enter the heart. The new replacement valve is expanded directly into the malfunctioning mitral valve. Complex CTO-PCI: The Japanese Approach This 20 minute video shows a complex CTO case, in which an RCA obstruction, complicated by a sharp bend and tortuous anatomy, was revascularized using both the antegrade and retrograde approaches, facilitated by IVUS and biplane angiographic imaging. The operator is Dr. Etsuo Tsuchikane; the case was broadcast live during the Japanese CTO Club course in June 2017. (from TCROSS NEWS) Clinical Trial to Study If 3-Months of DAPT is Safe After XIENCE Stent The study, called XIENCE Short DAPT, will evaluate if 3 months of DAPT is non-inferior to the current standard of 12 months after implantation with a XIENCE stent for patients who are at high risk of bleeding. The study will enroll approximately 2,000 patients at 100 sites in the U.S. and Asia. FDA OK to Medtronic's CoreValve for Patients at Intermediate Risk for Surgical Replacement Based on results from the SURTAVI Trial, the FDA has approved the CoreValve TAVR self-expanding platform for use in patients with symptomatic and severe aortic stenosis who are at intermediate risk for surgical valve replacement. "The Whole Story is About Increasing Patient Happiness." Interview with Dr. Ferdinand Kiemeneij In this two-part 20th anniversary interview, the "father of transradial intervention, " talks about the history and future of TRI. Angioplasty News Get our RSS News Feed Recent News: Medtronic Begins New SPYRAL Pilot Study for RDN (Feb 4) Interview with Tejas Patel and Samir Pancholy on Telerobotic PCI (Sep 23) FDA OK to Medtronic's Next-Gen Evolut™ PRO+ (Sep 23) IN.PACT AV Access Trial Meets Primary Safety and Effectiveness Endpoints (Sep 7) FDA Fast Tracks Shockwave IVL Device Review (Sep 3) FDA Approves SAPIEN3 TAVR for Low Risk Patients (Aug 16) FDA Approves CoreValve Evolut TAVR for Low Risk Patients (Aug 16) Siemens to Acquire Corindus Vascular Robotics (Aug 8) Dr. Watanabe Discusses the Results of the STOPDAPT-2 RCT (Jul 25) Philips Launches IntraSight Platform, integrating physiology, imaging and co-registration tools (May 20) Bringing Japanese Know-How to the Global Market: A Visit to Shimadzu Medical Systems (Apr 24) FDA OK to Resolute DES for Use in Chronic Total Occlusions (Feb 26) Medtronic Valiant™ Captivia™ Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients (Jan 30) Philips Launches Azurion with FlexArm (Jan 17) Medtronic Launches Mobile App for Smartphone-Connected Pacemakers (Jan 15) Abiomed Invests $15M in Shockwave (Dec 11) In Honor of #VEITH2018: The First EVAR (Nov 13) Low Profile Valiant Navion Thoracic Stent System Garners CE Mark in Addition to FDA Approval (Nov 13) VIVA: 5-Yr Data for IN.PACT DCB Show Superiority over PTA (Nov 12) FDA Approval for Valiant Navion™ Thoracic Stent Graft System (Oct 23) New Data for IN.PACT DCB Show Superiority/Durability over PTA (Oct 2) Medtronic: 5-yr Outcomes for CoreValve; 2-yr Outcomes for SURTAVI (Sep 24) FDA Oks IN.PACT DCB Lengths of 200mm & 250mm (Jun 23) Resolute Onyx 1-Month OCT Study: 92.3% Stent Coverage (May 24) FDA Oks Abbott's Xience Sierra Everolimus-Eluting Stent (May 23) Shockwave Launches Coronary Lithotripsy System in Europe (May 21) Dr. Moriyama Discusses Study of BVS at Five Years (May 8) IN.PACT DCB Approved for Long Lesions Up To 360mm (Apr 23) FDA Approves Medtronic's 2.0mm Resolute Onyx (Feb 26) IN.PACT 2-Year Data Presented at LINC 2018 (Jan 30) 200 Patient Study: Abre Venous Self-Expanding Stent System in Patients with Deep Venous Disease (Jan 24) Medtronic: ENCHANT Study to Assess ChEVAR Parallel Graft Technique with Endurant II/IIs (Jan 24) 3-year Outcomes of Surgical vs. Endovascular Revasculization for CLI Patients (Jan 10) Outcomes after STEMI DES Same for 6 vs 12 ...